Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
about
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practiceCurrent and emerging therapies in unresectable and recurrent gastric cancerHER2 testing in gastric cancer: An updateCompanion diagnostics for the targeted therapy of gastric cancerHER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the StomachClinical practice guidelines for gastric cancer in Korea: an evidence-based approachUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsThe genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondA novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancersEGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?Proceedings of the 1st Puerto Rico Biobanking Workshop.Molecular classification of gastric cancer: a new paradigm.Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerOverexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer.Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expressionmiR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expressionPrognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancerTumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing.Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer.HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridizationAberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.Primary and acquired resistance to biologic therapies in gastrointestinal cancers.Biologic therapy in esophageal and gastric malignancies: current therapies and future directionsComparison of HER2 expression between primary colorectal cancer and their corresponding metastases.Clinical impact of tumour biology in the management of gastroesophageal cancerHER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patients.Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomasGenome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridizationHuman Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsHER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the LiteratureHER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.HER2/neu testing in primary colorectal carcinoma.Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
P2860
Q26741253-904393BF-8ABE-4F5D-80E8-D7099CF25272Q26745453-055DA3BB-1AA4-4F8A-A4D8-249B62A9FAF0Q26746253-E53A5E21-F28E-4658-B3DE-60CE927759F6Q26780298-098A303C-595B-429A-8C10-1424998F47E8Q26780318-5B2C6A3F-D295-424A-8C43-B79E31D2180CQ26828506-6DEF8AFE-B62C-43E5-8C86-5A0A3B994658Q27691330-918EE5BD-B64B-4239-9750-82C096B0116DQ28077666-A7640DB0-1647-4D13-921B-40CE82F69A93Q28078111-E1D0D647-3A40-4762-8408-70FFF04F721DQ28078788-6B42DA4A-86E7-4E75-9CE0-837976BEB5CDQ28485310-5CA242DD-E3FC-4191-9E2B-C464D42A2F4FQ28538710-4E2DDB76-EF5E-4758-82E4-BC304F6E526FQ30399341-DB2123C8-5836-4BCB-A2F2-0863AA24DC6AQ30500375-F3791055-C981-46AD-90F4-3709E7030B6EQ30724810-7DA7EA2F-5B67-474B-997C-1D497828374CQ30837184-A636A567-64B1-41ED-811D-CCB1816BBA77Q33557258-401A7D19-7EDC-428D-9861-11A29530FBFBQ33613022-49748697-6E1C-4118-96E3-00038B01B132Q33626875-413BC9CD-3131-4477-91A0-BEA79A4789B7Q33690070-E623C6C9-638E-468E-A4F4-38CF5C603CF9Q33706171-1867F7FD-965C-475B-B8BE-A01B97F9672CQ33733751-1AD0CFD2-1422-4569-995B-4A81DF8288F7Q33733858-15514F1C-0E6A-4519-9C64-D5BB786F5AE5Q33764191-E65536E5-1B2D-414E-9218-BFF465973022Q33799233-9ACE6CF7-798F-44C7-A7AC-358833560331Q33863322-6EAB8343-65AA-4952-8831-50F31D3C581CQ33873317-D63BE222-1CFD-49F3-A31B-D07BBDA25B79Q33895573-8CD242BD-2CBD-4B9F-BDF5-85CA8FA13F0CQ33895597-763E7504-59EC-488D-BA51-C3083CC317C0Q33913610-44F8ABB3-AEE4-4FBA-9B6D-F4191247A44EQ33922534-B493C169-502F-47A6-9955-02F53D9E9262Q33925610-3C6324E1-8B22-42A7-A023-EF687003C9A9Q34029360-57F20ECF-EEF2-4EE6-B8E5-33A73E611B37Q34052477-8E4ADE3C-5ABB-4BE7-B155-FC22C9E2B726Q34216289-CCEC48FB-7F9D-4D03-AF31-711051A0BB8BQ34223494-E5F345F7-7292-46A3-B7E2-B7830AD89086Q34223664-C4B64186-841B-4CE5-8ACC-5668FC83865AQ34324291-AF0AE372-E015-41CC-A633-EC4493F2B521Q34499615-24F3F089-0EC8-4FC8-9995-19849F00E2A4Q34538368-DC5F7CDB-0FBB-4BC8-A550-6259A2C5EEDA
P2860
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
@en
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
@nl
type
label
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
@en
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
@nl
prefLabel
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
@en
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
@nl
P2093
P1433
P1476
Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
@en
P2093
J Rüschoff
P304
P356
10.1111/J.1365-2559.2008.03028.X
P577
2008-04-18T00:00:00Z